Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smokisone: Prednisone on Airway Inflammatory Response to Inhaled Wood Smoke
NCT03861390Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prednisone in airway inflammation (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Change From Baseline in Sputum Percent Neutrophils at 24 hours. Started Mar 2019; status: completed.
02
Drugs
prednisone
03
Conditions
airway inflammation
Beyond the preview
Go deeper on NCT03861390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861390.